Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED.
Andrea Sartore-Bianchi is the Director of the Division of Clinical Research and Innovation at Grande Ospedale Metropolitano Niguarda in Milano, Italy, and Associate Professor of Oncology at the University of Milano. He received his MD and postgraduate degree in Oncology at the University of Pavia, Italy, and subsequently conducted preclinical research at Brown University, Providence, RI, USA.
His main clinical and research interests include precision oncology and the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to targeted therapies. He is principal and co-investigator in Phase I-III clinical trials for solid tumours and carried out initial studies paving the way for the use of RAS and Her2 as tumor tissue/ctDNA biomarkers in colorectal cancer. He has published 200 peer-reviewed articles in various medical journals with a H-index of 62 (Scopus).
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Navigating common treatment scenarios in HER2-mutant non-small cell lung cancer
An overview of the EMERALD subgroup analyses
A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC
Survey findings presented at ONS 2025 and published in the journal Healthcare
Combining locoregional and systemic treatments in intermediate HCC